In this edition of “In the Spotlight,” we are excited to introduce Debarati Biswas, the dynamic Product Manager at LARVOL. With a lifelong fascination for drug research and a career spanning various facets of healthcare and equity research, Debarati brings a unique perspective to her role. Her journey from childhood experiences with medicine to becoming a key player in oncology at LARVOL is both inspiring and enlightening. Join us as we delve into her story, exploring her professional passions, motivations, and the unique qualities she brings to the LARVOL team.
From a young age, I've been exposed to the medical field having been surrounded by illnesses and hospitalizations, sparking a lifelong fascination with medicine. While I was never drawn to becoming a doctor, my passion for drug research and data analysis guided my career path. At LARVOL, I serve as the Product Manager for LARVOL PULSE, where I stay abreast of the latest developments in cancer treatment and other drug therapies.
My journey into healthcare began with a profound interest in drug research, which eventually led me to analyze healthcare stocks at an equity research firm. In search of a more adaptable work environment, I explored remote opportunities and discovered LARVOL—a place that seemed tailor-made for my skills and interests.
Being part of LARVOL’s diverse team is amazing! We have a respectful work environment where everyone brings their unique perspective to the table. It’s like working with a pack of high-performing tigers – we’re fast and on a mission. Nearly a decade of remote work have sharpened my ability to effectively communicate, honed my ability to read situations accurately and develop into a versatile professional.
The chance to delve into drug research is inherently motivating. The constant learning keeps me engaged and happy, like a daily dose of dopamine. When faced with challenges, I focus on what I can control. Work itself is a form of therapy for me, allowing me to stay present and avoid getting overwhelmed.
Outside of work, one of my lesser-known skills is handwriting analysis. I have a knack of understanding people through the way they write, which often surprises those who know me professionally.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm